Evidence map›Paper›PMID 27638340›Full record

ReviewJournal of molecular medicine (Berlin, Germany)2016

Zinc and zinc-containing biomolecules in childhood brain tumors.

Jan Hrabeta, Tomas Eckschlager, Marie Stiborova, Zbynek Heger, Sona Krizkova, Vojtech Adam

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular medicine (Berlin, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. ZnT7 RNAi favors RafOncogene · 2021
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. The Metallome of Lung Cancer and its Potential Use as Biomarker.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jan HrabetaDepartment of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, University Hospital Motol, Charles University, V Uvalu 84, CZ-150 06, Prague 5, Czech Republic.
Tomas EckschlagerDepartment of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, University Hospital Motol, Charles University, V Uvalu 84, CZ-150 06, Prague 5, Czech Republic.
Marie StiborovaDepartment of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-128 40, Prague 2, Czech Republic.
Zbynek HegerDepartment of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00, Brno, Czech Republic.
Sona KrizkovaDepartment of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00, Brno, Czech Republic.
Vojtech AdamDepartment of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00, Brno, Czech Republic. vojtech.adam@mendelu.cz.
Charles University · CZMendel University in Brno · CZCentral European Institute of Technology · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zinc ions are essential cofactors of a wide range of enzymes, transcription factors, and other regulatory proteins. Moreover, zinc is also involved in cellular signaling and enzymes inhibition. Zinc dysregulation, deficiency, over-supply, and imbalance in zinc ion transporters regulation are connected with various diseases including cancer. A zinc ion pool is maintained by two types of proteins: (i) zinc-binding proteins, which act as a buffer and intracellular donors of zinc and (ii) zinc transporters responsible for zinc fluxes into/from cells and organelles. The decreased serum zinc ion levels have been identified in patients suffering from various cancer diseases, including head and neck tumors and breast, prostate, liver, and lung cancer. On the contrary, increased zinc ion levels have been found in breast cancer and other malignant tissues. Zinc metalloproteomes of a majority of tumors including brain ones are still not yet fully understood. Current knowledge show that zinc ion levels and detection of certain zinc-containing proteins may be utilized for diagnostic and prognostic purposes. In addition, these proteins can also be promising therapeutic targets. The aim of the present work is an overview of the importance of zinc ions, zinc transporters, and zinc-containing proteins in brain tumors, which are, after leukemia, the second most common type of childhood cancer and the second leading cause of death in children after accidents.

Indexed as

Brain NeoplasmsChildHumansModels, BiologicalMolecular Targeted TherapyNeoplasm ProteinsZincNeoplasm ProteinsZincCancerChildhood brain tumorsMetallothioneinsZinc metalloenzymesZinc transporters

Identifiers

PMID27638340
OpenAlexW2520864526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.